3,312 research outputs found

    Phenotyping the haemostatic system by thrombography:Potential for the estimation of thrombotic risk

    Get PDF
    The aim of this paper is to review the thrombogram and its use for phenotyping the haemostatic system. The thrombogram can be readily obtained through Calibrated Automated Thrombography (CAT), using a commercially available fluorometer, dedicated software (Thrombinoscope (R)) and a calibrator. Here we explore the possibility to use platelet-rich plasma (PRP) triggered with a low amount of recombinant human tissue factor (similar to 0.5 pM) and also explore the function of the protein C system by adding activated protein C (APC) or soluble recombinant thrombomodulin (TM). Examples are shown: inherited antithrombin (AT) and protein C deficiencies, and antiphospholipid antibodies. (c) 2004 Elsevier Ltd. All rights reserved

    Granulation sèche des poudres : Influence des paramètres du procédé

    Get PDF
    National audienceDans un but d'optimisation du procédé de granulation sèche de poudres, une presse à rouleaux instrumentée a été développée. Une première campagne d'essais a permis de visualiser le profil des contraintes à la surface des rouleaux en fonction de l'angle de rotation, ainsi que l'allure des différents paramètres (couple, effort, entrefer) au cours de l'essai

    Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations

    Get PDF
    We read with much interest the recent observational study of Nougier et al., which aimed at studying thrombin generation (TG) and fibrinolysis profiles of COVID-19 patients admitted to an intensive care unit (ICU) or to an internal medicine ward and receiving various schemes of prophylactic heparin.[1] They reported that thrombin potential remained within normal range despite heparin and that fibrinolysis was decreased in relation with increased plasminogen activator inhibitor 1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) antigen plasma levels. Using the rotational thromboelastometry (ROTEM) delta device with EXTEM reagents and the addition of 0.625µg/mL tPA (referred to as 'TEM-tPA'), they reported decreased clot lysis in COVID-19 patients, which was more pronounced in patients who presented a thrombotic event, compared to event-free patients

    Variability among commercial batches of normal pooled plasma in lupus anticoagulant testing

    Get PDF
    Lupus anticoagulant (LA) testing requires normal pooled plasma (NPP) in performing mixing studies and can be used for normalized ratios of clotting times (CTs). The aims were to demonstrate whether significant differences in clotting times between two batches of a same commercial NPP (CRYOcheck™) directly affect NPP-based cut-off values. Diluted Russell Viper venom time (DRVVT) and activated partial thromboplastin time (aPTT) were used for LA testing. Screening, mixing and confirm tests were performed with Stago® instruments and reagents. Two batches of commercial NPP (A1291 and A1301 from CRYOcheck™; frozen) were compared in the determination of cut-off values. Cut-off values were defined as 99th percentile values of 60 healthy donors and compared with Mann-Whitney U test. Cut-off values obtained with the two NPP batches were significantly different for DRVVT (screen normalized ratio: 1.09 vs. 1.24, screen mix: 41.9 s vs. 38.9 s; index of circulating anticoagulant: 5.0 vs. 8.4; all had p-value <.001). On the contrary, no significant differences were observed for aPTT (screen normalized ratio: 1.32 vs. 1.34; p-value = .4068, screen mix: 37.8 s vs. 38.1 s; p-value = .1153) except for index of circulating anticoagulant: 9.6 versus 10.4 (p-value <.05). This study demonstrates that differences between two commercial NPP batches produced by a same manufacturer influenced LA cut-off values used for mixing studies and normalized ratios. Adequate cut-off setting, taking into account NPP CTs, is important to provide accurate conclusion about the presence or absence of a LA and avoid potential clinical impact
    • …